[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares Common Stock] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [4 March China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Selling Stockholders Shares Underwriting Agreement We understand that 3,870,000 shares of Common Stock are to be sold by certain stockholders] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – March 1, 2016 The shares to be sold in this offering represent approximately 13.2 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] [China Biologic Announces Pricing of Secondary Offering of Common Stock BEIJING, China – March 2, 2016 China Biologic will not sell any shares of common stock in the offering and will not receive any proceeds from the sale of the Purchased Shares or the Additional Shares. prospectus@morganstanley.com This press release shall not constitute an offer to sell or the solicitation] []

[CHINA BIOLOGIC PRODUCTS, INC. AMENDED AND RESTATED DIRECTOR AGREEMENT Agreement Company Mr. David Li Director THIS AGREEMENT (this “ BACKGROUND Original Agreement The Director and the Company entered into a director agreement (the “ The Director and the Company desire to enter into this Agreement to amend and restate the Original Agreement in its entirety. AGREEMENT In consideration for the] [FOR RELEASE February 25, 2016 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2015 4Q15 Total Sales Up 22.6% with Non-GAAP Net Income Up 44.5% YoY in RMB terms, or Up 17.8% YoY to $68.3 Million and 38.8% YoY to $20.4 Million in USD terms, respectively FY15 Total Sales Up 23.4% with Non-GAAP Net Income Up] []